08:50 AM EDT, 03/15/2024 (MT Newswires) -- Arch Biopartners Inc. ( ACHFF ), (ARCH.V) announced Friday that a research team from the University of Calgary's Cumming School of Medicine has joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). LSALT peptide is the company's lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

The addition of the first Canadian clinical site increases the number of trial sites to four, with three hospitals in Turkey recruiting patients. There are three additional hospital sites in Turkey pending activation into the trial. The Arch Biopartners ( ACHFF ) team is working with two other hospital sites in Canada to prepare for their participation in this Phase II trial.

The CS-AKI Phase II trial is an international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide. The recruitment target for the trial is 240 patients. The primary objective of the trial is to evaluate the percentage of subjects with AKI within seven days following on-pump (heart-lung machine) cardiac surgery.